South Korea Nonalcoholic Steatohepatitis Treatment Market was valued at USD 0.2 Billion in 2022 and is projected to reach USD 0.4 Billion by 2030, growing at a CAGR of 7.5% from 2024 to 2030.
South Korea's Nonalcoholic Steatohepatitis (NASH) treatment market is witnessing significant growth, driven by the escalating prevalence of liver diseases and the urgent need for effective therapeutic interventions. Between 2010 and 2022, the incidence of Nonalcoholic Fatty Liver Disease (NAFLD) in South Korea surged from 1.87% to 4.47%, while prevalence rates climbed from 10.49% to 17.13%. This alarming trend underscores the pressing demand for advanced NASH treatments.
The South Korean liver disease therapeutics market, valued at $337 million in 2022, is projected to reach $567 million by 2030, reflecting a compound annual growth rate (CAGR) of 6.7%. This growth is fueled by factors such as the rising incidence of liver diseases and evolving lifestyle patterns.
The pharmaceutical landscape in South Korea is marked by the presence of key domestic players like Bukwang Pharm, Dong-A ST, and LISCure Biosciences, who are instrumental in developing and distributing liver disease therapeutics. Their contributions are vital in addressing the country's growing NASH burden.Globally, the NASH treatment market is on an upward trajectory, with projections estimating it will reach $33.80 billion by 2030, growing at a CAGR of 28.1% from 2025 to 2030. This expansion is largely attributed to the introduction of novel drugs such as Novo Nordisk's Ozempic, Intercept's Ocaliva, and Inventiva's lanifibranor. Notably, the U.S. Food and Drug Administration approved resmetirom in March 2024, marking a significant milestone in NASH therapeutics.The increasing prevalence of NASH is closely linked to the rising rates of obesity and diabetes, conditions that are becoming more prevalent in South Korea. This correlation highlights the necessity for integrated treatment approaches that address both liver health and metabolic disorders.Despite the promising developments in NASH therapeutics, challenges remain. Many South Korean patients with viral hepatitis are unaware of their infection status, leading to delays in seeking treatment. Additionally, the invasive nature of liver biopsies, the current gold standard for NASH diagnosis, limits early detection. These factors underscore the need for enhanced public awareness and the development of non-invasive diagnostic tools.In response to these challenges, South Korea's healthcare industry is focusing on several key areas:- **Research and Development:** Investing in the creation of innovative, effective, and safe NASH treatments.- **Public Awareness Campaigns:** Educating the populace about liver health, risk factors, and the importance of early diagnosis.- **Non-Invasive Diagnostics:** Developing and implementing less invasive diagnostic methods to facilitate early detection and treatment initiation.Addressing the NASH epidemic in South Korea requires a collaborative effort among pharmaceutical companies, healthcare providers, and policymakers. By focusing on innovation, education, and accessibility, the nation can make significant strides in combating this growing health concern.
Get an In-Depth Research Analysis of the South Korea Nonalcoholic Steatohepatitis Treatment Market Size And Forecast [2025-2032]
AstraZeneca
Arena Pharmaceuticals
GSK
Novo Nordisk
Roche
Vivus
Arisaph Pharmaceuticals
Cempra Pharmaceuticals
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the South Korea Nonalcoholic Steatohepatitis Treatment Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the South Korea Nonalcoholic Steatohepatitis Treatment Market
Antidiabetic Medications
Vitamin E
Obeticholic Acid
Other Investigational Drugs
Oral Administration
Injectable Administration
Intravenous Administration
Public Hospitals
Private Hospitals
Children (0-14 years)
Adults (15-64 years)
Seniors (65 years and above)
With Fibrosis
Without Fibrosis
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ South Korea Nonalcoholic Steatohepatitis Treatment Market Research Analysis
1. Introduction of the South Korea Nonalcoholic Steatohepatitis Treatment Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. South Korea Nonalcoholic Steatohepatitis Treatment Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. South Korea Nonalcoholic Steatohepatitis Treatment Market, By Type
6. South Korea Nonalcoholic Steatohepatitis Treatment Market, By Application
7. South Korea Nonalcoholic Steatohepatitis Treatment Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. South Korea Nonalcoholic Steatohepatitis Treatment Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/